It has been shown that total plasma and LDL-cholesterol reduction, using HMG-CoA-reductase inhibitors, is an effective and well tolerated tool in the prevention of coronary heart disease (CHD). The most recent trials included a high number of subjects: even those with only moderately elevated plasma cholesterol levels took part. Treatment with statins was particularly useful in secondary cardiovascular prevention. Radiological procedures confirmed the benefits of the drug at the vascular level, as regards plaque stabilization, endothelium-improved arterial tone, as well as reduction of stenotic lesions. Elderly subjects, particularly those who are less than 75 years of age and who are affected by CHD, seem to benefit a great deal from these drugs. Nevertheless, we still lack specific studies which address this issue in this age group. Pharmaco-economic analysis indicated that the cost/effectiveness of HMG-CoA reductase inhibitors differs significantly among the different cardiovascul r...
I trial clinici sull'uso delle statine nella cardiopatia ischemica
VIGNA, Giovanni Battista;VOLPATO, Stefano;ZULIANI, Giovanni
1997
Abstract
It has been shown that total plasma and LDL-cholesterol reduction, using HMG-CoA-reductase inhibitors, is an effective and well tolerated tool in the prevention of coronary heart disease (CHD). The most recent trials included a high number of subjects: even those with only moderately elevated plasma cholesterol levels took part. Treatment with statins was particularly useful in secondary cardiovascular prevention. Radiological procedures confirmed the benefits of the drug at the vascular level, as regards plaque stabilization, endothelium-improved arterial tone, as well as reduction of stenotic lesions. Elderly subjects, particularly those who are less than 75 years of age and who are affected by CHD, seem to benefit a great deal from these drugs. Nevertheless, we still lack specific studies which address this issue in this age group. Pharmaco-economic analysis indicated that the cost/effectiveness of HMG-CoA reductase inhibitors differs significantly among the different cardiovascul r...I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
